Lower Austria Innovation Prize 2016 – CROMA-PHARMA wins Karl Ritter von Ghega Award
The winners will be rewarded with a prize of € 10,000, - to receive the award as Lower Austrian Innovation Prize winner and the exclusive opportunity to participate in the "State Prize for Innovation".
CROMA-PHARMA´s CTO Mr. Martin Prinz received the award on behalf of the entire R & D team. All steps of research and development have been accomplished in-house.
The core of innovation:
Eye drops containing Thio-polymers cause the production of the tear film in patients with a dry eye even with just a single daily use.
"1 application - 12 hours effect" - a revolution in dry eyes
Patients with dry eye or Sicca syndrome, a very common problem in the age of computer workstations, suffer from burning, itching, and aching eyes that ignite during non-treatment, which in turn causes damage to the cornea. Conventional, commercially available products moisturize the surface of the eye in the short term, but they are removed from the cornea at every blink of the eye. In order to achieve a longer-term symptom relief, these products have to be administered repeatedly. Lacrimera® succeeds in reconstructing a physiological tear film for more than 12 h with the aid of the innovative thiomer technology on which this product is based. The adherence of the effective hydrophilic biopolymer prevents leaching or ablation from the cornea for hours.
Conventional products for the treatment of the dry eye are removed from the eye surface with every blink of the eye and must therefore often be given hourly. With Lacrimera®, the physiological tear film thickness can be restored with a single application.
Sustainability: With the development of Lacrimera®, we have succeeded in bringing an effective preparation onto the market, which reduces the comfort and well-being of millions of patients with a dry eye by reducing the frequency of application once a day.